Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

PURPOSE: Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growth factor receptor. Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Choueiri, Toni K., Ross, Robert W., Jacobus, Susanna, Vaishampayan, Ulka, Yu, Evan Y., Quinn, David I., Hahn, Noah M., Hutson, Thomas E., Sonpavde, Guru, Morrissey, Stephanie C., Buckle, Geoffrey C., Kim, William Y., Petrylak, Daniel P., Ryan, Christopher W., Eisenberger, Mario A., Mortazavi, Amir, Bubley, Glenn J., Taplin, Mary-Ellen, Rosenberg, Jonathan E., Kantoff, Philip W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4104290/
https://ncbi.nlm.nih.gov/pubmed/22184381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.7002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados